Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020

share with twitter share with LinkedIn share with facebook
08/07/2020 | 08:31am EDT

LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system and ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin at 11:00 a.m. EDT on Friday, August 14, 2020.

To participate in the call, interested parties may dial 1-800-353-6461 (Toll-Free/North America) or 1-334-323-0501 (International/Toll) and ask for the Celsion Corporation Second Quarter 2020 Earnings Call (Conference Code: 4777957) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com. The call will be archived for replay on Friday, August 14, 2020 and will remain available until August 28, 2020. The replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID: 4777957. An audio replay of the call will also be available on the Company's website, www.celsion.com, for 90 days after 2:00 p.m. EDT Friday, August 14, 2020.

About Celsion Corporation

Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit: http://www.celsion.com. (CLSN-FIN).

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact                                                                   LHA Investor Relations         
Jeffrey W. Church                                                                                 Kim Sutton Golodetz
Executive Vice President & CFO                                                          212-838-3777                         
609-482-2455                                                                                       kgolodetz@lhai.com
jchurch@celsion.com

# # #

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about CELSION CORPORATION
10/16CELSION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
10/12CELSION CORPORATION : Issues Letter to Stockholders
AQ
10/12Celsion Corporation Issues Letter to Stockholders
GL
09/08CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/08CELSION : Announces Common Stock Purchase Agreement with Lincoln Park Capital an..
AQ
09/08Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital a..
GL
09/04CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02CELSION CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/02Celsion Corporation Restructures its Strategic Loan Facility
GL
08/14CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,85x
Yield 2020 -
Capitalization 20,5 M 20,5 M -
Capi. / Sales 2020 40,7x
Capi. / Sales 2021 82,2x
Nbr of Employees 29
Free-Float 98,6%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,00 $
Last Close Price 0,57 $
Spread / Highest target 604%
Spread / Average Target 604%
Spread / Lowest Target 604%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-66.77%21
GILEAD SCIENCES, INC.-6.82%75 938
REGENERON PHARMACEUTICALS53.57%61 364
VERTEX PHARMACEUTICALS-2.01%57 436
WUXI APPTEC CO., LTD.63.88%38 230
BEIGENE, LTD.80.92%27 326